Company Profile

Galenea Corporation
Profile last edited on: 3/6/22      CAGE: 5EK82      UEI:

Business Identifier: Synaptic transmission (ST): process by which neurons communicate with each other
Year Founded
2003
First Award
2009
Latest Award
2012
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

50C Audubon Road
Wakefield, MA 01880
   (617) 374-1010
   info@galenea.com
   www.galenea.com
Location: Single
Congr. District: 06
County: Middlesex

Public Profile

Galenea Corporation is focused on developing drugs that treat neurodegenerative central neurvous system (CNS) diseases via the modulation of synaptic transmission: the process by which neurons communicate. The company uses an integrated drug discovery approach that utilizes its proprietary Multiwell Automated NeuroTRansmission Assay (MANTA) synaptic screening technology for primary neurons and neurons developed from human stem cells. The company is also focused on preclinical network measures based on MANTRA screening and is developing clinical biomarkers based on brain activity in humans as measured by electroencephalogram (EEG) for use in clinical development. Intitially based on research on the role of calcineurin in the pathogenisis of schizophrenia, the companny's discovery platform also generated a therapeutics program for cognitive impairment, and discovery programs in Huntington's disease and neurodegeneration.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Mark B Benjamin -- President and CEO

  Jianzhu Chen -- Founder

  David Julian Gerber -- Founder Vice President, CNS Research

  Maria Karayiorgou -- Founder

  Silvana Leit

  Jonathan Max Levenson

  David Neafus -- CFO

  John Oyler -- former President

  Lisa R Paborski -- Corporate Development

  Adam Rosenberg -- Corporate Development

  Susumu Tonegawa -- Founder